By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Dyax Corp. 

55 Network Drive

Burlington  Massachusetts  01803  U.S.A.
Phone: 617-225-2500 Fax: 617-225-2501


SEARCH JOBS

Founded in 1995, Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key areas of focus are the KALBITOR® (ecallantide) business and the Angioedema Portfolio, as well as the Licensing and Funded Research Program (LFRP).

Dyax discovered and developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside of the United States, the Company has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and is evaluating opportunities in others. Currently, Dyax has collaboration agreements for regions including Europe, Japan, Russia, the Middle East, Australia and New Zealand. Dyax is also exploring other potential indications for KALBITOR, either alone or through collaborations.

The Company is expanding its portfolio for the treatment of angioedemas by identifying diagnostic strategies to assist in the differentiation between histamine-mediated and plasma kallikrein (bradykinin) mediated (PKM) angioedema, and developing a fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, which could be a candidate to prophylactically treat PKM angioedemas.

KALBITOR and DX-2930 were identified using Dyax’s patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 11 product candidates in various stages of clinical development, including three in Phase 3 trials.

Dyax is headquartered in Burlington, Massachusetts. For online information about Dyax Corp., please visit www.dyax.com.


Key Statistics


Email: ir@dyax.com
Ownership: Public

Web Site: Dyax Corp.
Employees: 120
Symbol: DYAX
 



Industry
Biotechnology


Collaborations

CMIC Co., Ltd.  Ecallantide in HAE and other angioedemas indications

Sigma-Tau Group  Ecallantide in HAE and other therapeutic indications

Eli Lilly  Antibody phage display

Amgen  Antibody phage display

Merrimack Pharmaceuticals Inc.  Antibody phage display

Sanofi-Aventis (New Jersey)  Antibody phage display

Biogen Idec  Antibody phage display

Genzyme Corporation  Hereditary Angioedema





Company News
Dyax Corp. (DYAX)'s First-In-Human Trial For DX-2930 Conducted By Vince And Associates Clinical Research Featured In The Annals Of Allergy, Asthma & Immunology 12/18/2014 10:59:57 AM
Dyax Corp. (DYAX) To Participate In The 25th Annual Oppenheimer Healthcare Conference 12/3/2014 10:17:41 AM
Dyax Corp. (DYAX) Recognized As A "Top Place To Work" By The Boston Globe 11/18/2014 4:31:33 PM
Dyax Corp. (DYAX) Announces Expansion Of Phase 1b Clinical Trial For DX-2930 11/3/2014 12:27:32 PM
Dyax Corp. (DYAX) Announces Third Quarter 2014 Financial Results 10/29/2014 8:51:45 AM
Dyax Corp. (DYAX) To Host Third Quarter 2014 Earnings Call And Webcast 10/14/2014 8:41:24 AM
Dyax Corp. (DYAX) To Participate In The Leerink Partners Rare Disease Roundtable 9/25/2014 9:41:02 AM
Dyax Corp. (DYAX) Highlights Recent Progress In Licensing And Funded Research Portfolio 9/22/2014 1:31:23 PM
Dyax Corp. (DYAX) Announces Issuance Of Two Key U.S. Patents For DX-2930 9/15/2014 11:50:44 AM
Dyax Corp. (DYAX) Announces Second Quarter 2014 Financial Results 7/30/2014 10:39:16 AM
12345678910...
//-->